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Previously published studies on levels of the transform-
ing growth factor-β1 (TGF-β1) protein and mRNA of the 
corresponding gene in patients suffering from inflam-
matory bowel diseases (IBD) gave varying results, lead-
ing to contradictory conclusions. To solve the contradic-
tions, we aimed to assess longitudinally TGF-β1 protein 
and mRNA levels at different stages of the disease in 
children suffering from IBD. The study group consisted of 
19 pediatric patients with IBD at the age between 3.5 and 
18.4 years. The control group consisted of 42 children aged 
between 2.0 and 18.0 years. The plasma TGF-β1 concentra-
tion was measured with ELISA. mRNA levels of the TGF-β1 
gene isolated from samples of the intestinal tissue were 
assessed by reverse transcription and real-time PCR. Levels 
of TGF-β1 protein in plasma and corresponding mRNA in 
intestinal tissue were significantly higher in IBD patients 
than in controls. TGF-β1 and corresponding transcripts 
were also more abundant in plasma and intestinal tis-
sue, respectively, in patients at the active stage of the 
disease than during remission. In every single IBD pa-
tient, plasma TGF-β1 level and mRNA level in intestinal 
tissue was higher at the active stage of the disease than 
during remission. Levels of TGF-β1 and corresponding 
mRNA are elevated during the active stage of IBD but 
not during the remission. Longitudinal assessment of 
this cytokine in a single patient may help to monitor the 
clinical course of IBD.
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INTRODUCTION
Transforming growth factor-β1 (the isoform 1 of trans-
forming growth factor type beta, abbreviated as TGF-β1) is 
a cytokine with immunomodulatory activity (Li et al., 2006; 
Rahimi & Leof, 2007). It is known to affect cell prolifer-
ation and development (Heldin et al., 2009). This cytokine 
has an immunosuppressive function, and thus it was de-
scribed as a factor involved in preventing autoimmune 
and chronic inflammatory reactions (Bommireddy et al., 
2006; Saxena et al., 2008). Because of its effects on im-
munological response, it is not a surprise that levels of 
both the TGF-β1 protein and mRNA of the correspond-
ing gene were determined in patients suffering from in-
flammatory bowel disease (IBD), a chronic inflammation 
which occurs in two main clinical forms: Crohn’s dis-
ease (CD) and ulcerative colitis (UC). However, different 
studies gave varying results, leading to contradictory con-
clusions on the involvement of TGF-β1 in IBD. 
In the early report on expression of the TGF-β gene, 
an increased level of corresponding mRNA was detected 
by in situ hybridization in affected mucosa from patients 
with both CD and UC with active disease (Babyatsky et 
al., 1996). In tissue samples from these patients, TGF-β1 
mRNA localized mostly to cells of the lamina propria 
with the highest expression in inflammatory cells clos-
est to the luminal surface. It was, therefore, concluded 
that TGF-β may be a key cytokine during periods of ac-
tive inflammation, modulating epithelial cell restitution 
and functional features of cells within the lamina pro-
pria (Babyatsky et al., 1996). Similar results were report-
ed three years later, when increased levels of TGF-β1 
mRNA, relative to controls, in tissue samples from CD 
patients were measured, and localization of this cytokine 
(assessed by immunohistochemistry) was predominant 
in lamina propria cells and in the lymphocytes closest 
to the luminal surface (di Mola et al., 1999). Neverthe-
less, enhanced expression of the TGF-β1 gene was also 
evident in epithelial cells, and fibroblasts of CD tissue 
samples (di Mola et al., 1999). Contrary to those reports, 
another research group reported an unchanged expres-
sion (relative to the control group) of TGF-β1 in the co-
lonic epithelium of adolescent IBD patients (as assessed 
by in situ hybridization), despite an increased number of 
TGF-β1-positive cells in the lamina propria, during the 
active stage of the disease (Xian et al., 1999).
Even more doubts about the expression of the 
TGF-β1 in IBD patients appeared when plasma lev-
els of this cytokine were determined. Although base-
line TGF-β1 levels were higher in UC patients than in 
controls, after 7 days of a conventional treatment con-
centration of this cytokine increased in patients who re-
sponded to the therapy, but not in those who did not 
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respond (Sambuelli et al., 2000). These results suggest-
ed a negative correlation between TGF-β1 plasma lev-
els and the activity of the disease. On the other hand, a 
parallel study demonstrated that TGF-β1 plasma concen-
trations were not significantly different in IBD (CD and 
UC) patients and healthy controls (Sturm et al., 2000). 
Moreover, stratification of IBD patients according to the 
disease activity also did not reveal any substantial differ-
ences (Sturm et al., 2000). Another group found a high-
er level of TGF-β1 in plasma of pediatric IBD patients 
(both CD and UC) during remission than at the active 
stage of the disease (Kader et al., 2005). In contrast, oth-
er authors reported no significant differences in the plas-
ma level of TGF-β1 between IBD patients and controls, 
while considerably higher TGF-β1 level occurred in UC 
patients during active disease than at the remission stage 
(Kilic et al., 2009). Furthermore, an increased plasma 
TGF-β1 level was also reported in pediatric UC patients 
in comparison to controls (Wedrychowicz et al., 2011).
Recent works reported an enhanced expression of 
the TGF-β1 gene in intestinal tissue of CD (Burke et al., 
2008) and UC (Stadnicki et al., 2009) patients relative to 
controls. Interestingly, it has been suggested that high 
levels of TGF-β1 in healthy bowels of patients who un-
dergo ileo-colonic resection for CD are associated with 
early clinical disease recurrence (Scarpa et al., 2009). Fi-
nally, when pediatric IBD (both CD and UC) patients 
were investigated, TGF-β1 mRNA levels were signifi-
cantly higher in intestinal tissue samples collected during 
the relapse of the disease than in those taken during the 
remission or in the control group, while no statistical-
ly significant differences in plasma TGF-β1 levels were 
found between any of these groups (though a tendency 
for higher levels in IBD patients was observed with bor-
derline p value of 0.06) (Liberek et al., 2013). In addition, 
higher levels of mRNA of the TGF-β1 gene were evi-
dent in affected areas of intestinal tissue derived from 
IBD pediatric patients than in unaffected areas of the 
same patients (Liberek et al., 2013).
The short review of studies on levels of expression 
of the gene coding for TGF-β1 in IBD patients, pre-
sented above, indicates that there are discrepancies be-
tween results reported by various groups, which led to 
contradictory conclusions on TGF-β1 levels during the 
disease, relative to controls. We assumed that one of 
the problems that might cause obtaining such differ-
ent results in various studies might arise from the fact 
that levels of either TGF-β1 protein or corresponding 
mRNA were compared between samples obtained from 
different groups of patients, i.e. in cross-sectional stud-
ies. To solve these contradictions, we used a longitudinal 
approach by comparing results obtained from biological 
samples of the same patients taken at different stages of 
the disease. Besides calculating statistical values, we have 
also analyzed tendency of differences in the measured 
values in samples from each particular patient in the ac-
tive stage of the disease and during remission.
MATERIALS AND METHODS
Patients. The study group consisted of 19 patients with 
IBD (10 boys and 9 girls), among which 7 were diagnosed 
for CD and 12 for UC at the age between 3.5 and 18.4 
years (mean 13.0±4.5 y, median 14.5 y). All IBD (CD and 
UC) patients were treated with the usual anti-inflamma-
tory drug (5-aminosalicylic acid, 5ASA) at the standard 
recommended doses. A group of 42 children represented 
the control group, which consisted of 20 girls and 22 boys 
at the age between 2.0 and 18.0 years (mean 11.0±5.0 y, 
median 11.0 y), who underwent endoscopy because of epi-
sodes of gastrointestinal (GI) bleedings; in this group of 
patients, inflammatory processes, immune disorders, malig-
nancies and nutritional abnormalities were excluded. None 
of the children from the control group received immuno-
modulating drugs at least 6 months prior to the study.
Clinical procedures. Among IBD patients, severity of 
CD and UC were estimated according to the Hyams scale 
(Pediatric Crohn’s Disease Activity Index, PCDAI) and 
the Truelove-Witts scale, respectively (Truelove & Witts, 
1954; Hyams et al., 1991). In all IBD patients, both blood 
and bowel tissue samples were obtained (during endoscopy 
in the latter cases, where all samples were colonic) in the 
acute phase of the disease and in remission. Endoscopic 
and histological classifications of intestinal mucosa were 
performed according to the Porto criteria (IBD Working 
Group of the European Society for Paediatric Gastro-
enterology, Hepatology and Nutrition, 2005). In children 
from the control group, the samples were withdrawn 
once, when performing obligatory diagnostic procedures.
Estimation of TGF-β1 level in plasma. The plasma 
TGF-β1 level was estimated by ELISA as described pre-
viously (Liberek et al., 2013), and according to the man-
ufacturer’s instruction (Quantikine TGF-β1 R&D Systems, 
USA).
 Estimation of mRNA level of the gene coding for 
TGF-β1. mRNA levels of the TGF-β1 gene in samples of 
the intestinal tissue were estimated by reverse transcription 
and real-time PCR as described previously (Liberek et al., 
2013). Briefly, total RNA was isolated by employing the 
Total RNA Prep Plus kit (A&A Biotechnology, Poland). 
Each reverse transcription reaction was performed in to-
tal volume of 10 μl, with 1 μg of RNA, 0.25 μg of oligo 
T18, and M-MLVenzyme (Promega, Madison, WI, USA). 
For real-time PCR reactions, primers specific to TGF-β1 
(primers annotated TGF-β1 and TGFβ-2) and the con-
trol gene ACTB (primers annotated bact1-1 and bact1-2), 
described previously (Liberek et al., 2013), were used (the 
sequences of these primers were as follows: TGF-β1: 5′-
CAG CAA CAA TTC CTG GCG ATA CC; TGFβ-2, 
5′-CGA AAG CCC TCA ATT TCC CCT C; bact1-1, 5′-
TGT GCC CAT CTA CGA GGG GTA TGC; bact1-2, 
5′-GGT ACATGG TGG TGC CGC CAG ACA). Each 
real-time PCR reaction was performed in total volume 
of 20 μl, with 0.4 μl cDNA, 180 nM each of two spe-
cific primers and iQSybrGreen Supermix kit (Bio-Rad), 
employing iCycler iQ (Bio-Rad). The reactions were run 
in triplicates and the data obtained were averaged. Data 
analysis and calculations were done with iQ ver. 3.1 soft-
ware (Bio-Rad). The results for the ACTB gene were 
used as controls to normalize the values in the ΔΔCt 
quantification method.
Statistical analysis. Statistical analysis of the results 
was performed using non-parametric tests: the Mann-
Whitney test for comparison of two groups, the ANOVA 
Kruskal-Wallis test for comparison of several groups. For 
comparison of values obtained from the same patient at 
different stages of the disease, the Wilcoxon signed rank 
test for paired values was used. The results were consid-
ered statistically significant when p < 0.05. The calculations 
were performed employing Statistica 7 software (StatSoft 
Inc. Tulsa, OK, USA).
Ethical considerations. This study was approved by 
the Independent Bio-Ethical Committee for Research at 
the Medical University of Gdańsk (NKEBN/13/2004). 
Informed consent was obtained from parent(s) of each 
patient included in the study.
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RESULTS
Since previously published studies reported contradic-
tory results of estimation of levels of the TGF-β1 pro-
tein and mRNA of the corresponding gene in plasma 
and intestine tissue of patients suffering from IBD (re-
viewed in Introduction). In order to solve these contra-
dictions, we have measured these parameters in pediatric 
patients with IBD (the groups with CD and UC were in-
cluded, but no statistically significant differences between 
these two groups were detected in all measured parame-
ters, with p>0.05 in each analysis, therefore, CD and UC 
patients will be described together as IBD patients in 
further text). However, contrary to previous studies, we 
have not only considered mean values or medians from 
the studied groups relative to those of controls, but we 
also compared protein and mRNA levels in samples 
from every single patient taken at the active disease and 
during remission. Therefore, despite the fact that such a 
study required double endoscopy for every patient, we 
were able to compare not only statistical parameters of 
particular groups, but also to observe changes in the 
measured biochemical parameters occurring in every sin-
gle patient at different stages of the disease.
When estimating levels of the TGF-β1 protein in plas-
ma (Table 1), we found that the median concentration 
of this protein was significantly higher in IBD patients 
than in controls (6.03 ng/ml (range: 2.0–14.44) vs. 2.79 
ng/ml (range: 0.54–55.1) p=0.005). TGF-β1 was also 
more abundant in plasma of patients being at the active 
stage of the disease than in plasma of the same group 
of patients during remission (6.03 ng/ml (range: 2.0–
14.44) vs. 1.94 ng/ml (range: 0.96–7.09) p=0.03). How-
ever, no statistically significant differences were observed 
between patients at the remission stage and the control 
group (p=0.26). Importantly, in every single IBD patient, 
plasma TGF-β1 level was higher at the active stage of 
the disease than during remission (p < 0.001). These dif-
ferences were pronounced to various extent in different 
patients, nevertheless, no exception from the rule was 
noted (Fig. 1).
Because of these intriguing results, we have ana-
lyzed levels of mRNA of the gene coding for TGF-β1 
in samples of intestinal tissue withdrawn from con-
trols (single endoscopy) and from IBD patients during 
both stages of the disease (two endoscopic events 
for each patient, one at the active disease stage and 
another one during remission) (Table 2). We have 
calculated that the median TGF-β1 mRNA level (ex-
pressed in arbitrary units) was higher in patients at the 
active disease stage than in controls (0.08453 (range: 
0.00291–0.31250) vs. 0.04028 (range: 0.00103–0.82469) 
Figure 1. Comparison of plasma TGF-β1 concentrations (ng/ml) in the group of IBD patients at the active stage of the disease and during 
the remission. 
Each line represents changes in TGF-β1 levels observed in a single patient separately. The results obtained for each particular patient are 
represented by the same kind and color of symbols and lines in this figure and in Fig. 2. Statistical analysis indicated a significantly higher 
plasma TGF-β1 level at the active stage of the disease than during remission (p<0.001).
Table 1. Plasma TGF-β1 concentration in the control group, and in the group of IBD patients, measured at the active stage of the disease 
and during the remission.
Group N
Plasma TGF-β1 concentration (ng/ml)b
Mean Median Min. Max. SD
Controla 42 6.96 2.79 0.54 55.10 11.60
IBD patients 19
Active disease 7.10 6.03 2.00 14.44 4.16
Remission 2.41 1.94 0.96 7.09 1.73
aThis group of patients was reported previously (Liberek et al., 2013). bStatistical analysis:  the median in IBD patients at the active stage vs. controls, 
p=0.005; the median in IBD patients during remission vs. controls, p=0.26; the median in IBD patients at the active stage vs. the same group of 
patients during remission, p=0.03.
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p=0.002), however, the difference in this parameter 
between patients during remission and the control 
group did not reach statistical significance (p=0.05). 
When we compared two stages of the disease in 
the same group of patients, we found that the me-
dian level of TGF-β1 mRNA was higher during the 
active disease than during remission (0.08453 (range: 
0.00291–0.31250) vs. 0.00906 (range: 0.00191–0.21250) 
p<0.001). More importantly, we found that in every 
single patient, TGF-β1 mRNA level measured at the 
active disease stage was higher than during remission 
(p<0.001). No exception from this rule was found 
(Fig. 2).
DISCUSSION
TGF-β1, a cytokine with generally immunosuppres-
sive activity, undoubtedly plays a role in gut inflamma-
tion, including IBD (MacDonald et al., 2001). Neverthe-
less, during the last two decades, several articles were 
published in which various authors measured levels of 
TGF-β1 or mRNA of the corresponding gene under 
various conditions, and reported increased levels in IBD 
patients vs. controls, decreased levels in IBD patients vs. 
controls or no significant differences (see Introduction 
for details). These contradictory results are intriguing, es-
pecially in the light of discussions on molecular mecha-
nisms by which TGF-β1 might influence IBD (MacDon-
ald et al., 2001).
Because of the above problem, we have performed 
studies towards solving the contradictions reported in 
previous publications. Our intention was to compare 
not only mean values or other statistical parameters, 
like median, obtained after analyses of samples from 
different groups under study, but also to compare 
changes in the protein or mRNA levels in every IBD 
patient at two stages of the disease: the active stage 
and the remission. Our results indicated that (apart 
from significantly increased levels of TGF-β1 and 
corresponding mRNA in plasma and intestinal tissue, 
respectively, in IBD patients relative to the control 
group) in each IBD patient, plasma TGF-β1 level was 
higher at the active stage of the disease than during 
remission, and in each IBD patient, TGF-β1 mRNA 
level in intestinal tissue was higher at the active stage 
of the disease than during remission. Importantly, in 
both analyses, no single exception from the rule was 
found, i.e. the measured TGF-β1 protein and corre-
sponding mRNA levels were higher during the active 
disease than during remission in every single patient. 
In Figs. 1 and 2, showing levels of TGF-β1 protein 
Table 2. Levels of mRNA of the TGF-β1 gene in intestinal tissue samples taken from members of the control group, and from the 
group of IBD patients undergoing endoscopy twice:  at the active stage of the disease and during the remission.
Group N
Levels of mRNA of the TGF-β1 gene (arbitrary units)b
Mean Median Min. Max. SD
Controla 42 0.08591 0.04028 0.00103 0.82469 0.16012
IBD patients 19
Active disease 0.11557 0.08453 0.00291 0.31250 0.09229
Remission 0.03305 0.00906 0.00191 0.21250 0.06448
aThis group of patients was reported previously (Liberek et al., 2013). bStatistical analysis:  the median in IBD patients at the active stage vs. controls, 
p=0.002; the median in IBD patients during remission vs. controls, p=0.05; the median in IBD patients at the active stage vs. the same group of 
patients during remission, p<0.001.
Figure 2. Comparison of mRNA levels of the TGF-β1 gene (arbitrary units) in intestinal tissue samples taken from IBD patients at the ac-
tive stage of the disease and during the remission. 
Each line represents changes in levels of mRNA of the TGF-β1 gene observed in a single patient separately. The results obtained for each par-
ticular patient are represented by the same kind and color of symbols and lines in this figure and in Fig. 1. Statistical analysis indicated a 
significantly higher TGF-β1 mRNA level at the active stage of the disease than during remission (p<0.001).
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and mRNA, respectively, the results obtained for each 
particular patient are represented by the same kind 
and color of symbols and lines. It appears that in 
some patients a very high level of the TGF-β1 protein 
in plasma correlated with a high mRNA level of the 
corresponding gene in intestinal tissue, however, the 
fold differences between active disease and remission 
was not necessary the same for protein and mRNA 
levels in individual patients. This is not a surprise, as 
different kinds of biological material (plasma vs. in-
testinal tissue) were used for measurement of protein 
and mRNA amounts. Nevertheless, the direction and 
tendency of changes in these parameters were the 
same in each patient. Therefore, we conclude that ex-
pression of the gene coding for TGF-β1 is enhanced 
during the active stage of IBD, relative to remission 
of the disease, at least in pediatric patients.
The question remains as to the reasons for reported 
contradictions in levels of TGF-β1 in IBD patients. 
One might suggest a possible influence of genetic 
background of different groups of patients investigat-
ed by different authors, particularly polymorphisms of 
the TGF-β1 gene. However, recent studies indicated a 
lack of correlation between common polymorphisms 
in this gene and clinical parameters of IBD (Liber-
ek et al., 2011). Therefore, it is more likely that the 
problems with contradictory results could arise from 
technical difficulties of studies. One obvious difficulty 
is based on collecting an appropriate control group. 
Usually a control group consists of patients suffer-
ing from other diseases rather than from healthy vol-
unteers. Such a situation takes place especially often 
when invasive procedures are employed, which may 
be exemplified by endoscopy used in this and similar 
studies. Although for many investigations such com-
position of a control group might not result in any 
problems, in studies focused on TGF-β1 this may 
cause potential difficulty because this cytokine is in-
volved in various immunological reactions, and thus, 
its level may be altered in a number of diseases un-
related to IBD. If this is the case, and if a patient, 
or several patients, with a transiently increased or de-
creased expression of TGF-β1 is/are included in the 
control group, the mean and/or median control val-
ue(s) could be significantly influenced, giving false ref-
erence value in comparison to the studied group of 
patients.
The reality of the problem described above may 
be demonstrated even in this study. When analyz-
ing the values of plasma TGF-β1 level (Table 1), it 
is intriguing that although in vast majority of samples 
withdrawn from members of the control group the 
level was generally low, the maximal detected value 
was dramatically higher than that in any IBD patient. 
Such values may affect the statistical analyses con-
siderably when mean values are calculated. Note that 
such a high maximal value of the plasma TGF-β1 lev-
el was detected in the control group despite the fact 
that in this group of patients, inflammatory processes, 
immune disorders, malignancies and nutritional ab-
normalities were excluded, and none of the patients 
received immuno-modulating drugs at least 6 months 
prior to the study (as described in Materials and 
Methods). Moreover, a similar phenomenon was ob-
served when the mRNA level was estimated (Table 2); 
in this test, the maximal level detected in the control 
group was over 10 times higher than the mean value 
and over 20 times higher than the median. Therefore, 
we suggest that in such cases, comparison of partic-
ular parameters in each patient at different stages of 
the disease may be especially informative, and can be 
considered together with analyses based on calculation 
and comparison of mean or median values from dif-
ferent groups. If a longitudinal assessment of particu-
lar parameters is possible for many individual patients, 
and if a general tendency is observed in most or even 
all patients, the conclusions might be considered as 
especially well supported by experimental results.
Finally, since the results of TGF-β1 protein and 
mRNA levels presented in Figs. 1 and 2 are so unequiv-
ocal, we suggest that longitudinal assessment of this cy-
tokine in a single patient may help to monitor the clini-
cal course of IBD.
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